Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany

  • Objective: Dravet syndrome (DS) is a rare but severe drug-resistant epilepsy. Before the approval of fenfluramine (FFA) for the treatment of seizures in DS, patients in Germany could receive treatment under a compassionate use program (CUP). Methods: We conducted a multicenter, retrospective, observational study to describe the efficacy, tolerability, and retention of FFA within the CUP. Patients received add-on therapy with oral FFA gradually titrated to a target dose between .13 and .7 mg/kg/day Results: Overall, 78 patients with DS (median age = 8.0 years, range = 2.1–46.0; 53% female, median concomitant antiseizure medications [ASMs] = 3) were treated with FFA for a median duration of 255.5 days (range = 31–572). Responder rates (a ≥50% reduction; n = 78) and seizure-freedom rates at 3 months were 68% and 14% for total seizures, respectively, and 67% and 23% for generalized tonic–clonic seizures. Responder rates were consistent at 6 and 12 months (n = 66 and n = 43, respectively). Median seizure days per month significantly decreased from 10.0 (range = .5–30) to 3.0 (range = 0–30) in the 3-month period before and after FFA treatment (p < .001). Significantly fewer patients reported at least one episode of status epilepticus (28% vs. 14% patients before and after FFA initiation, p = .005). During FFA treatment, 35 (45%) patients were able to discontinue a concomitant ASM. At the last follow-up date, 66 (85%) patients remained on treatment with FFA. The most common adverse events were somnolence (36%), decreased appetite (22%), and ataxia (8%). Forty-eight (62%) patients were reported as having a meaningful global clinical improvement. Significance: In a large cohort of patients, FFA demonstrated efficacy across a range of outcomes including clinically significant reductions in convulsive seizures, and was well tolerated, providing valuable information for real-world practice.

Download full text files

Export metadata

Metadaten
Author:Adam StrzelczykORCiDGND, Milka Pringsheim, Thomas Mayer, Tilman PolsterGND, Kerstin Alexandra Klotz, Hiltrud Muhle, Michael Alber, Regina TrollmannGND, Hartwig Spors, Gerhard Kluger, Gerhard KurlemannGND, Susanne Schubert-BastORCiDGND
URN:urn:nbn:de:hebis:30:3-645175
DOI:https://doi.org/10.1111/epi.17034
ISSN:1528-1167
Parent Title (English):Epilepsia
Publisher:Wiley-Blackwell
Place of publication:Oxford [u.a.]
Document Type:Article
Language:English
Date of Publication (online):2021/08/10
Date of first Publication:2021/08/10
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2021/12/21
Tag:Clinical Global Impression of Change; Dravet syndrome; convulsive seizures; fenfluramine; real-world; status epilepticus
Volume:62
Issue:10
Page Number:10
First Page:2518
Last Page:2527
Note:
This study was supported by a LOEWE grant to A.S. and S.S.-B. from the State of Hessen for the Center for Personalized Translational Epilepsy Research, Goethe University Frankfurt, Frankfurt am Main, Germany. K.A.K. was supported by the Berta Ottenstein Program for Clinician Scientists from the Faculty of Medicine, University of Freiburg, Germany.
HeBIS-PPN:490814417
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (English):License LogoCreative Commons - Namensnennung-Nicht kommerziell 4.0